Publications by authors named "James Freston"

Claim this Profile
C
Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials.
David H Alpers, James H Lewis, Christine M Hunt, James W Freston, Vicente E Torres

Am J Kidney Dis· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis.
William R Treem, Melissa Palmer, Isabelle Lonjon-Domanec, Daniel Seekins, Lara Dimick-Santos, James W Freston

Drug Saf· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study.
Daniel C Beachler, Cynthia de Luise, Aziza Jamal-Allial, Ruihua Yin, Devon H Taylor, James W Freston

BMC Cancer· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development.
Arie Regev, Mark I Avigan, Alexandre Kiazand, John M Vierling, James H Lewis, James W Freston

J Autoimmun· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis.
Arie Regev, Melissa Palmer, Mark I Avigan, Lara Dimick-Santos, William R Treem, James W Freston

Aliment Pharmacol Ther· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liver Complications Following Treatment of Hematologic Malignancy With Anti-CD22-Calicheamicin (Inotuzumab Ozogamicin).
George B McDonald, James W Freston, James L Boyer, Laurie D DeLeve

Hepatology· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and histopathologic features of fluoroquinolone-induced liver injury.
Eric S Orman, Hari S Conjeevaram, Raj Vuppalanchi, James W Freston, James Rochon

Clin Gastroenterol Hepatol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Presentation of the Julius M. Friedenwald Medal to David A. Peura, MD, AGAF.
James W Freston, Cynthia M Yoshida

Gastroenterology· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work.
Ayako Suzuki, Raul J Andrade, Einar Bjornsson, M Isabel Lucena, William M Lee, James W Freston

Drug Saf· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method.
Don C Rockey, Leonard B Seeff, James Rochon, James Freston, Naga Chalasani

Hepatology· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term quality of life improvement in subjects with healed erosive esophagitis: treatment with lansoprazole.
Thomas O Kovacs, James W Freston, Marian M Haber, Stuart Atkinson, Barbara Hunt

Dig Dis Sci· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US.
Keith G Tolman, James W Freston, Stuart Kupfer, Alfonso Perez

Drug Saf· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy of lansoprazole in preventing relapse of erosive reflux esophagitis.
Thomas O Kovacs, James W Freston, Marian M Haber, Barbara Hunt, Stuart Atkinson

Dig Dis Sci· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lansoprazole for long-term maintenance therapy of erosive esophagitis: double-blind comparison with ranitidine.
David A Peura, James W Freston, Marian M Haber, Thomas O Kovacs, Barbara Hunt

Dig Dis Sci· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of pH-impedance testing to evaluate patients with suspected extraesophageal manifestations of gastroesophageal reflux disease.
Ashish Malhotra, James W Freston, Khalid Aziz

J Clin Gastroenterol· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recurrent pneumonia from severe nonacid reflux: a case report and discussion.
Ashish Malhotra, James W Freston, Maria Soriano, Khalid Aziz

Conn Med· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proton pump inhibitors: effective first-line treatment for management of dyspepsia.
David A Peura, Jeff Gudmundson, Nancy Siepman, Betsy L Pilmer, James Freston

Dig Dis Sci· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancing patient care: integrating new data.
Teresa L Wright, Canan Avunduk, Jules L Dienstag, James W Freston, Ira M Jacobson

Am J Gastroenterol· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Our new president-David a. Peura, MD.
James W Freston, Cynthia M Yoshida

Gastroenterology· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic choices in reflux disease: defining the criteria for selecting a proton pump inhibitor.
James W Freston

Am J Med· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Do children with gastroesophageal reflux become adults with gastroesophageal reflux? What is the role of Acid suppression in children?
John T Boyle, John Co, Geoffrey Davidson, James Freston, Suzanne Nelson

J Pediatr Gastroenterol Nutr· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gastroesophageal reflux in children: pathogenesis, prevalence, diagnosis, and role of proton pump inhibitors in treatment.
Benjamin D Gold, James W Freston

Paediatr Drugs· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lansoprazole for maintenance of remission of erosive oesophagitis.
James W Freston, Robert L Jackson, Bidan Huang, E David Ballard

Drugs· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Motion - All patients with GERD should be offered once in a lifetime endoscopy: arguments against the motion.
James W Freston

Can J Gastroenterol· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis